You are here

Article info

Article menu
Download PDFPDF
Correspondence
Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE”

Authors

  • Guillermo J Pons-Estel Departament of Rheumatology, Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina PubMed articlesGoogle scholar articles
  • Manuel F. Ugarte-Gil Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru Universidad Científica del Sur, Lima, Peru PubMed articlesGoogle scholar articles
  • Guillermina B Harvey Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina PubMed articlesGoogle scholar articles
  • Bernardo A Pons-Estel Departament of Rheumatology, Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina PubMed articlesGoogle scholar articles
  • Graciela S Alarcón Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Medicine, School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Guillermo J Pons-Estel, Departament of Rheumatology, Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina; gponsestel{at}hotmail.com
View Full Text

Citation

Pons-Estel GJ, Ugarte-Gil MF, Harvey GB, et al
Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE”
Annals of the Rheumatic Diseases 2023;82:e189.

Publication history

  • Received June 17, 2021
  • Accepted June 18, 2021
  • First published August 3, 2021.
Online issue publication 
July 13, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.